Literature DB >> 25806300

Oligometastatic NSCLC: the changing role of surgery.

Eric Vallières1.   

Abstract

There is a very limited role for pulmonary resection in the management of NSCLC that has already metastasized systemically. Well selected individuals who present with limited metastatic disease (oligometastases) to a single organ may be considered for resection or an alternative local therapy to both the lung and the extrapulmonary site in rare instances where a thorough metastatic evaluation fails to reveal other foci of disease. This evaluation must include a negative mediastinoscopy.

Entities:  

Keywords:  Lung cancer; oligometastases

Year:  2014        PMID: 25806300      PMCID: PMC4367693          DOI: 10.3978/j.issn.2218-6751.2014.06.06

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


  12 in total

1.  The dandelion effect: treat the whole lawn or weed selectively?

Authors:  Minesh Mehta
Journal:  J Clin Oncol       Date:  2010-12-06       Impact factor: 44.544

2.  Surgical treatment of solitary adrenal metastasis from non-small cell lung cancer.

Authors:  Olaf Mercier; Elie Fadel; Marc de Perrot; Sacha Mussot; Franco Stella; Alain Chapelier; Philippe Dartevelle
Journal:  J Thorac Cardiovasc Surg       Date:  2005-07       Impact factor: 5.209

3.  Non-small cell lung cancer with single brain metastasis: the role of surgical treatment.

Authors:  P Granone; S Margaritora; A D'Andrilli; A Cesario; K Kawamukai; E Meacci
Journal:  Eur J Cardiothorac Surg       Date:  2001-08       Impact factor: 4.191

4.  Multiple primary lung cancers.

Authors:  N Martini; M R Melamed
Journal:  J Thorac Cardiovasc Surg       Date:  1975-10       Impact factor: 5.209

5.  Surgical treatment of primary lung cancer with synchronous brain metastases.

Authors:  P S Billing; D L Miller; M S Allen; C Deschamps; V F Trastek; P C Pairolero
Journal:  J Thorac Cardiovasc Surg       Date:  2001-09       Impact factor: 5.209

6.  Diagnostic accuracy of MRI compared to CCT in patients with brain metastases.

Authors:  P D Schellinger; H M Meinck; A Thron
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

7.  Treatment of brain metastases in patients with non-small cell lung cancer (NSCLC) by stereotactic linac-based radiosurgery: prognostic factors.

Authors:  Angelika Zabel; Stefanie Milker-Zabel; Christoph Thilmann; Ivan Zuna; Bernhard Rhein; Michael Wannenmacher; Jürgen Debus
Journal:  Lung Cancer       Date:  2002-07       Impact factor: 5.705

Review 8.  Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis.

Authors:  Tawee Tanvetyanon; Lary A Robinson; Michael J Schell; Vivian E Strong; Rachna Kapoor; Daniel G Coit; Gerold Bepler
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544

9.  A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis.

Authors:  Robert J Downey; Kenneth K Ng; Mark G Kris; Manjit S Bains; Vincent A Miller; Robert Heelan; Mark Bilsky; Robert Ginsberg; Valerie W Rusch
Journal:  Lung Cancer       Date:  2002-11       Impact factor: 5.705

Review 10.  Does surgery for primary non-small cell lung cancer and cerebral metastasis have any impact on survival?

Authors:  Amit Modi; Hunaid A Vohra; David F Weeden
Journal:  Interact Cardiovasc Thorac Surg       Date:  2009-01-20
View more
  2 in total

Review 1.  Current treatment landscape for oligometastatic non-small cell lung cancer.

Authors:  Javier Garde-Noguera; Margarita Martín-Martín; Andres Obeso; Miriam López-Mata; Inigo Royo Crespo; Lira Pelari-Mici; O Juan Vidal; Xabier Mielgo-Rubio; Juan Carlos Trujillo-Reyes; Felipe Couñago
Journal:  World J Clin Oncol       Date:  2022-06-24

Review 2.  Surgical approaches in patients with oligometastatic non-small cell lung cancer.

Authors:  Luca Bertolaccini; Alessandro Pardolesi; Sergio Nicola Forti Parri; Barbara Bonfanti; Jury Brandolini; Piergiorgio Solli
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.